Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.

Drew W. Rasco,Nehal J. Lakhani,Yuefen Tang,Hengbang Wang,Jiao Ji,Jason Chen,Zhiyan Liang,Alex Amaya,Dajun Yang,Yifan Zhai

Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.

2020

Drew W. Rasco
Nehal J. Lakhani
Yuefen Tang
Hengbang Wang
Jiao Ji
Jason Chen
Zhiyan Liang
Alex Amaya
Dajun Yang
Yifan Zhai

3508Background: APG-1387 is an IAP (inhibitor of apoptosis proteins) antagonist that has strong antitumor activity in multiple xenograft cancer models and acts as a host immune modulator, supportin...

Keywords:

Pembrolizumab
Pathology
Bivalent (genetics)
Medicine
iap antagonist
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations